Rikke Fredslund Andersen

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Cell-Free Nucleic Acids 84%
3. Circulating Tumor DNA 83%
4. DNA 48%
5. Biomarkers 47%
6. Mutation 39%
7. MicroRNAs 37%
8. Ovarian Neoplasms 36%
9. Drug Therapy 35%
10. Rectal Neoplasms 34%
11. Single Nucleotide Polymorphism 34%
12. Neoplasms 33%
13. Survival 28%
14. Bevacizumab 26%
15. Irinotecan 26%
16. Ovarian Epithelial Carcinoma 26%
17. Vascular Endothelial Growth Factor A 25%
18. Chemoradiotherapy 24%
19. Homeobox Genes 23%
20. Progression-Free Survival 23%
21. Methylation 22%
22. Polymerase Chain Reaction 20%
23. Therapeutics 17%
24. Circulating MicroRNA 16%
25. Non-Small Cell Lung Carcinoma 16%
26. Capecitabine 16%
27. Genotype 14%
28. ErbB Receptors 14%
29. Lung Neoplasms 13%
30. Genes 13%
31. gemcitabine 12%
32. Epidermal Growth Factor 11%
33. Poly(ADP-ribose) Polymerase Inhibitors 11%
34. Breast Neoplasms 10%
35. Liquid Biopsy 10%
36. Oxaliplatin 10%
37. Colonic Neoplasms 10%
38. Cetuximab 10%
39. Serum 10%
40. delta tocotrienol 9%
41. Gene Amplification 9%
42. Neuropeptide Y 9%
43. Complement C3d 9%
44. Vascular Endothelial Growth Factor Receptor-2 9%
45. Alleles 8%
46. Intracellular Signaling Peptides and Proteins 8%
47. regorafenib 8%
48. Platinum 8%
49. erbB-1 Genes 8%
50. Vascular Endothelial Growth Factors 8%